Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third-generation EGFR tyrosine kinase inhibitor Lazcluze (lazertinib) as a first ...

Jemperli – the seventh approved drug in the PD-1/PD-L1 inhibitor class – was acquired by GSK as part of its $5.1 billion takeover of Tesaro along with PARP inhibitor Zejula (niraparib ...

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

The stock market can be a scary place for those who aren’t prepared. Our writer outlines three ways we might avoid getting caught out.

GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary, advanced or ...

European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...

The label for Jemperli plus chemotherapy in the U.S. was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. Recently, GSK agreed to acquire IDRx ...

GSK’s Jemperli (dostarlimab) has been granted expanded approval by the European Commission (EC) to treat a broader range of endometrial cancer patients. The PD-1-blocking antibody has been authorised ...

(RTTNews) - GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line treatment of adult patients with primary advanced or ...

What are the Path of Exile 2 classes? The class you pick in Path of Exile 2 will define how you play the game. Some classes are glass cannons that opt to attack foes from a distance, while others ...